Literature DB >> 25701661

Palliative Sedation at the End of Life: Patterns of Use in an Israeli Hospice.

Daniel Azoulay1, Ruth Shahal-Gassner2, Malka Yehezkel2, Ester Eliyahu2, Nir Weigert2, Eliana Ein-Mor3, Jeremy M Jacobs4.   

Abstract

Palliative sedation (PS) is indicated for refractory symptoms among dying patients. This retrospective descriptive study examines PS in an Israeli hospice. Palliative sedation was defined as PS to unconsciousness (PSU), PS proportionate to symptoms (proportional palliative sedation [PPS]), or intermittent PS (IPS). Among 179 patients who died during 2012, PS was used among 21.2% (n = 38): (PSU 34.2%, PPS 34.2%, and IPS 31.6%), using midazolam (n = 33/38), halidol (21/38), and concurrent morphine (n = 35/38). Indications included agitation (71%), pain (36.8%), and dyspnea (21%). Survival following initiation of PS was 73 ± standard deviation 54 hours. No differences in survival were observed according to who initiated the decision to use PS (patients/medical staff/family) or type of PS (PSU/PPS/IPS). Survival following PS was longest with higher sedative doses, an observation that may help dispel fears concerning the use of PS to hasten death.
© The Author(s) 2015.

Entities:  

Keywords:  end-of-life care; hospice; palliative care; palliative sedation; survival; terminal sedation

Mesh:

Substances:

Year:  2015        PMID: 25701661     DOI: 10.1177/1049909115572991

Source DB:  PubMed          Journal:  Am J Hosp Palliat Care        ISSN: 1049-9091            Impact factor:   2.500


  3 in total

Review 1.  Palliative Sedation for the Terminally Ill Patient.

Authors:  Ferdinando Garetto; Ferdinando Cancelli; Romina Rossi; Marco Maltoni
Journal:  CNS Drugs       Date:  2018-10       Impact factor: 5.749

Review 2.  How to measure the effects and potential adverse events of palliative sedation? An integrative review.

Authors:  Alazne Belar; María Arantzamendi; Sheila Payne; Nancy Preston; Maaike Rijpstra; Jeroen Hasselaar; Lukas Radbruch; Michael Vanderelst; Julie Ling; Carlos Centeno
Journal:  Palliat Med       Date:  2020-12-14       Impact factor: 4.762

3.  Forensic Toxicological and Medico-Legal Evaluation in a Case of Incongruous Drug Administration in Terminal Cancer Patients.

Authors:  Pascale Basilicata; Pasquale Giugliano; Giuseppe Vacchiano; Angela Simonelli; Rossella Guadagni; Angela Silvestre; Maria Pieri
Journal:  Toxics       Date:  2021-12-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.